EATG » R&D

R&D

GlaxoSmithKline Is Working on a Much Simpler HIV Treatment

While there have been quite a good number of patients on Tivicay® (dolutegravir) already, and some even see it as a revolutionary next step in treatment and the simplification of…

First review of EmERGE closed with positive opinion

The EATG has been working in the EmERGE project as the lead for the Dissemination and Popularisation Work Package. EmERGE will develop an mHealth (mobile health = health related services…

Switch from TDF to TAF improves kidney and bone markers

The Body reports: Proteinuria, albuminuria and bone mineral density (BMD) improved significantly in HIV-positive people with mild or moderate renal impairment who switched to once-daily coformulated elvitegravir, cobicistat, emtricitabine and tenofovir…

Matthias Wienold on BMJ Blogs – New tools for participation in research

Founding EATG member and researcher of patient involvement and participation in clinical trials and medicines development, Matthias Wienold not only serves as IAPO Board member but has been blogging for…

The European AIDS Treatment News (EATN) complete collection 1992 – 2001 is now available

The EATG published the European AIDS Treatment News (EATN) for 10 years. This “newsletter” disseminated information for expert patients and treatment activists working across Europe. It contained the latest about medicines development, clinical…

EUPATI public consultation continues

The fourth framework of guidance regarding “patient involvement in the ethical review of clinical trials” has now been added to the EUPATI public consultation and all members are invited to…

Betting on hepatitis C: how financial speculation in drug development influences access to medicines

Victor Roy and Lawrence King argue that the acquisition strategies of drug companies magnify development costs and leave the public paying twice—for research and high priced medicines To read the…

AIDS conference: Will the UN High-Level Panel report deliver R&D and access to medicines?

DURBAN, South Africa, July 20 – The lessons derived from the history of AIDS treatment have become a rallying call for civil society organisations globally. Not being able to afford…

Early collaboration – a recipe for solutions: drug development and treatment strategies may go hand in hand

Join this webinar held as part of EUPATI, a key project co-led by EATG How early in the development of a new medicine should the discussion between researchers and patients…

Panels brainstorm ideas on innovation and drug access

The quest of balance between encouraging medical innovation and the imperative of broad access to medicines has so far been elusive. Two Harvard University programmes jointly organised a workshop this…